Raymond James & Associates Relay Therapeutics, Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 26,277 shares of RLAY stock, worth $167,121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,277
Previous 18,406
42.76%
Holding current value
$167,121
Previous $202,000
7.92%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RLAY
# of Institutions
188Shares Held
127MCall Options Held
4.2KPut Options Held
1.7K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$177 Million2.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$75.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.8MShares$62.3 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY7.42MShares$47.2 Million4.98% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.88MShares$43.8 Million0.01% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $765M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...